Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etalocib

Drug Profile

Etalocib

Alternative Names: LY-293111; VML 295

Latest Information Update: 16 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Vernalis
  • Class Anti-inflammatories; Antineoplastics; Benzoic acids
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene B4 receptor antagonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Non-small cell lung cancer; Pancreatic cancer; Psoriasis; Ulcerative colitis

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 22 Jul 2011 Discontinued - Phase-II for Non-small cell lung cancer in Canada (PO)
  • 22 Jul 2011 Discontinued - Phase-II for Non-small cell lung cancer in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top